보호된 글: COMPLETE Commercialization_DRAFT_May2022

Drive Value, Minimize Risk  and Increase Speed to Market

이 콘텐츠는 비밀번호로 보호하지 않습니다. 이 콘텐츠를 보려면 아래에 비밀번호를 입력해주세요:

Related Articles

Reignite Established Brands — Actual Use Case

EVERSANA™ REIGNITE Commercialization serves as a catalyst for biopharma companies to address the management of their established brand portfolios. In a recent study, EVERSANA reviewed a comprehensive number of established brands and implemented the EVERSANA REIGNITE Commercialization model to slow financial loss and make a positive impact on revenue. With a combined investment, these established […]

Succeed When Others Fail: Avoiding 20% in Investment Waste During Launch

It’s a long-standing perception that pharma overspends during launch, but we did not have the data or methodology to understand or validate this notion. Until now.  New Research by the Numbers 10: Recent analysis across 10 traditional launches where the manufacturer opted to commercially launch a new drug  $345M: The total cost for a manufacturer […]

CHALLENGING TRADITION: The argument for integrated commercialization to improve operational agility

Today’s economics simply do not support building commercial capabilities from scratch, only to dismantle that infrastructure until the next need arrives. Manufacturers will spend approximately $200 million of commercialization costs over three years leading up to the launch of their product, yet 66% of drugs do not meet launch expectations.    In an era of specialty and […]

Case Study: Launching a New Therapy for HER2-Positive Metastatic Breast Cancer

When MacroGenics partnered with EVERSANA, they had less than five months to launch their first product in the midst of the global pandemic. To meet their timeline and streamlined launch, MacroGenics needed a commercialization partner with an end-to-end platform that would allow them to build their capabilities expeditiously and strategically.

A SpaceX Philosophy to Launching in Pharma

In thinking about the economics around the launch of pharmaceutical products, it is useful to compare the situation to another area that has seen its economics evolve in recent years: space travel. For decades, the only reusable space vehicle was NASA’s space shuttle. When the space shuttle was in operation, it could launch a payload […]

Reinventing Launch: The Gold Standard Of Drug Commercialization

In a world that is rapidly changing, we must evolve beyond traditional strategies to create true impact for patients. EVERSANA’s complete end-to-end commercialization model enables manufacturers to bring their drug to market at a fraction of the cost of “going it alone” or partnering with another pharmaceutical company.